CY1111512T1 - Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων - Google Patents

Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων

Info

Publication number
CY1111512T1
CY1111512T1 CY20111100121T CY111100121T CY1111512T1 CY 1111512 T1 CY1111512 T1 CY 1111512T1 CY 20111100121 T CY20111100121 T CY 20111100121T CY 111100121 T CY111100121 T CY 111100121T CY 1111512 T1 CY1111512 T1 CY 1111512T1
Authority
CY
Cyprus
Prior art keywords
optional
treatment
life anxiety
opioid
anxiety
Prior art date
Application number
CY20111100121T
Other languages
Greek (el)
English (en)
Inventor
Wolfgang Fleischer
Karen Reimer
Karin Gawora
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1111512T1 publication Critical patent/CY1111512T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Disintegrating Or Milling (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20111100121T 2004-06-08 2011-02-03 Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων CY1111512T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04013469A EP1604667A1 (en) 2004-06-08 2004-06-08 Opioids for the treatment of the restless leg syndrome
EP05754710A EP1781291B9 (en) 2004-06-08 2005-06-01 Opioids for the treatment of the restlessness of the lower limbs

Publications (1)

Publication Number Publication Date
CY1111512T1 true CY1111512T1 (el) 2015-08-05

Family

ID=34925286

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100121T CY1111512T1 (el) 2004-06-08 2011-02-03 Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων

Country Status (25)

Country Link
US (2) US20070185147A1 (enExample)
EP (3) EP1604667A1 (enExample)
JP (2) JP2008501742A (enExample)
KR (2) KR20070037485A (enExample)
CN (2) CN103394090A (enExample)
AT (1) ATE486603T1 (enExample)
AU (1) AU2005251445C1 (enExample)
BR (1) BRPI0511300A (enExample)
CA (1) CA2569742C (enExample)
CY (1) CY1111512T1 (enExample)
DE (1) DE602005024571D1 (enExample)
DK (1) DK1781291T3 (enExample)
ES (1) ES2355247T3 (enExample)
HR (1) HRP20110049T2 (enExample)
IL (1) IL179896A (enExample)
ME (1) ME01238B (enExample)
MX (1) MXPA06014391A (enExample)
NO (1) NO337890B1 (enExample)
NZ (1) NZ552430A (enExample)
PL (1) PL1781291T3 (enExample)
PT (1) PT1781291E (enExample)
RS (1) RS51573B (enExample)
SI (1) SI1781291T1 (enExample)
WO (1) WO2005120506A1 (enExample)
ZA (1) ZA200610477B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2568965A1 (en) 2010-05-10 2013-03-20 Euro-Celtique S.A. Combination of active loaded granules with additional actives
PH12012502083A1 (en) 2010-05-10 2017-07-26 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
CN103118668B (zh) * 2010-08-13 2016-07-06 欧洲凯尔特公司 黏结剂在制备贮藏稳定的制剂中的用途
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (enExample) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
FR2183546B1 (enExample) * 1972-05-10 1975-06-20 Servier Lab
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
PT1009387E (pt) * 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
JP2001526228A (ja) * 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
SK13312000A3 (sk) * 1998-03-27 2001-05-10 Pharmacia And Upjohn Company Použitie kabergolínu pri liečbe syndrómu nepokojných nôh
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
BR0208922A (pt) * 2001-04-19 2004-04-20 Warner Lambert Co Aminoácidos bicìclicos ou tricìclicos fundidos
CN1525851A (zh) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
JP2005515960A (ja) * 2001-05-11 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 乱用耐性のオピオイド投薬形態
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP2005512965A (ja) * 2001-09-24 2005-05-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
EP1492505B1 (en) * 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
KR101200869B1 (ko) 2012-11-13
JP2008501742A (ja) 2008-01-24
EP1781291B1 (en) 2010-11-03
ATE486603T1 (de) 2010-11-15
AU2005251445C1 (en) 2009-04-09
NZ552430A (en) 2008-09-26
EP2255808A3 (en) 2011-05-11
CA2569742C (en) 2011-03-22
JP2011137020A (ja) 2011-07-14
JP5774865B2 (ja) 2015-09-09
ZA200610477B (en) 2007-12-27
EP1781291B9 (en) 2011-08-31
KR20090089921A (ko) 2009-08-24
CN1984659A (zh) 2007-06-20
ES2355247T9 (es) 2011-11-03
US20070185147A1 (en) 2007-08-09
PT1781291E (pt) 2011-01-06
BRPI0511300A (pt) 2007-12-04
EP1604667A1 (en) 2005-12-14
HRP20110049T1 (en) 2011-02-28
NO20070113L (no) 2007-03-02
AU2005251445A1 (en) 2005-12-22
EP1781291A1 (en) 2007-05-09
NO337890B1 (no) 2016-07-04
EP2255808A2 (en) 2010-12-01
WO2005120506A1 (en) 2005-12-22
US20120172387A1 (en) 2012-07-05
CN103394090A (zh) 2013-11-20
AU2005251445B2 (en) 2008-09-04
HRP20110049T2 (hr) 2011-10-31
AU2005251445B8 (en) 2008-09-18
IL179896A0 (en) 2007-05-15
DK1781291T3 (da) 2011-02-07
DE602005024571D1 (de) 2010-12-16
ME01238B (me) 2011-08-31
MXPA06014391A (es) 2007-02-19
RS51573B (sr) 2011-08-31
CA2569742A1 (en) 2005-12-22
KR20070037485A (ko) 2007-04-04
ES2355247T3 (es) 2011-03-24
SI1781291T1 (sl) 2011-02-28
IL179896A (en) 2013-07-31
PL1781291T3 (pl) 2011-06-30

Similar Documents

Publication Publication Date Title
CY1111512T1 (el) Οπιοειδη για την αγωγη της ανησυχιας των κατω ακρων
DK1765349T3 (da) Opioider til behandling af kronisk obstruktiv lungesygdom
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
ATE474564T1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
SMT201200014B (it) Nalmefene cloridrato diidrato.
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
SI1940409T1 (sl) Nove zdravilske kombinacije za zdravljenje bolezni dihalnih poti
MX2011011618A (es) Agentes terapeuticos 713.
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
NO20072720L (no) Farmasoytiske sammensetninger basert pa NK2-antagonister for pediatrisk bruk
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
EA200970968A1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидо-4-пиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases
ITMI20060712A1 (it) Uso di aminaftone per la preparazione di un medicamento per il trattamento delle arteriopatie
MX2008011017A (es) Compuestos de receptor sigma.
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
ES1056960Y (es) Aparato dental intra-oral para el tratamiento del ronquido y la apnea del sueño.
TW200738640A (en) Substituted pyrazoline compounds, their preparation and use as medicaments